Evidence map›Paper›PMID 40506506›Full record

ArticleScientific reports2025

Intradialytic optical assessment of C-mannosyl tryptophan removal using spent dialysate.

Joosep Paats, Annika Adoberg, Liisi Leis, Jürgen Arund, Kai Lauri, Merike Luman, Risto Tanner, Jana Holmar, Kristjan Pilt, Ivo Fridolin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joosep PaatsDepartment of Health Technologies, Tallinn University of Technology, 19086, Tallinn, Estonia. joosep.paats@taltech.ee.
Annika AdobergDepartment of Health Technologies, Tallinn University of Technology, 19086, Tallinn, Estonia.
Liisi LeisDepartment of Health Technologies, Tallinn University of Technology, 19086, Tallinn, Estonia.
Jürgen ArundDepartment of Health Technologies, Tallinn University of Technology, 19086, Tallinn, Estonia.
Kai LauriDepartment of Health Technologies, Tallinn University of Technology, 19086, Tallinn, Estonia.
Merike LumanDepartment of Health Technologies, Tallinn University of Technology, 19086, Tallinn, Estonia.
Risto TannerDepartment of Health Technologies, Tallinn University of Technology, 19086, Tallinn, Estonia.
Jana HolmarDepartment of Health Technologies, Tallinn University of Technology, 19086, Tallinn, Estonia.
Kristjan PiltDepartment of Health Technologies, Tallinn University of Technology, 19086, Tallinn, Estonia.
Ivo FridolinDepartment of Health Technologies, Tallinn University of Technology, 19086, Tallinn, Estonia.

Funding

Estonian Ministry of Education and Research TK218Estonian Research Council, Estonia PRG2643Estonian Research Council, Estonia PSG819European Regional Development Fund 767572
6 · The paper itself

Abstract

C-mannosyl tryptophan (CMW), also known as C-glycosyltryptophan, is a novel biomarker that is strongly correlated to chronic kidney disease (CKD) incidence and progression risk and mortality among earlier stages of CKD patients prior to end stage kidney disease. This study determined concentrations of CMW in blood and spent dialysate of CKD patients on chronic hemodialysis (HD) for the first time, and investigated the possibility for optical estimation of CMW concentrations in spent dialysate, its intradialytic removal and time-averaged concentration (TAC) of CMW based on optical measurements of spent dialysate. In total, 264 pre- and postdialysis blood samples, and 528 spent dialysate samples from 88 HD sessions of 22 patients were analyzed using high pressure liquid chromatography and spectrophotometry. We identified that CMW concentrations in CKD patients on chronic HD are over 10 times higher compared to earlier reported CMW concentrations in healthy subjects. The concentration of CMW in spent dialysate can be monitored based on spectrophotometric analysis of spent dialysate (r > 0.939, standard error: 0.07 μmol/L) and it is possible to evaluate CMW-based HD adequacy parameters, such as reduction ratio, mass of total removed solute, and TAC without blood sampling. In future, optical monitoring of CMW could be potentially used to improve clinical management of hemodialysis patients.

Indexed as

Dialysis SolutionsRenal DialysisRenal Insufficiency, ChronicTryptophanAdultAgedBiomarkersChromatography, High Pressure LiquidFemaleHumansKidney Failure, ChronicMaleMiddle AgedSpectrophotometryBiomarkersDialysis SolutionsTryptophanC-glycosyltryptophanC-mannosyl tryptophanEnd stage kidney diseaseHemodialysisSpectrophotometric analysisUremic solutes

Identifiers

PMID40506506
PMCPMC12162850

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.